TABLE 2B.
Antibacterial activity of lenzimycins A and B (1-2) against additional clinical isolates of Enterococci.
| Strain | Remarks |
MIC (μg/mL) |
||||
| 1a | 2b | Vc | Td | Be | ||
| Enterococcus faecalis JH2-2 | Parent strain, vancomycin sensitive | 3.1 | 1.6 | 25 | 3.1 | 25 |
| Enterococcus faecalis BM4316 | JH2-2::Tn1546, inducible resistance, VanA-type VREf | 4.2 | 10.4 | >100 | >100 | 83 |
| Enterococcus faecalis JH2-2::I | JH2-2::Tn1549, inducible resistance, VanB-type VREf | 6.3 | 6.3 | >100 | 50 | 83 |
| Enterococcus faecalis JH2-2::I C1 | point mutation in vanS, constitutive resistance | 4.2 | 6.3 | 100 | 83 | 83 |
a lenzimycin A, blenzimycin B, cVancomycin, dTeicoplanin, eBacitracin, and fVancomycin-resistant Enterococci.